What is the dosing range for CJC-1295?

CJC-1295 is typically dosed at 100mcg (low), 200mcg (moderate), or 300mcg (high) mcg, administered once daily (Mod GRF) or twice weekly (DAC version). These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

What are the reported side effects of CJC-1295?

Reported side effects of CJC-1295 include: Water retention (especially early in protocol), Tingling or numbness in extremities, Injection site redness, Flushing (transient, shortly after injection), Fatigue or lethargy (uncommon).

Performance

CJC-1295

Also known as: CJC-1295 DAC, CJC-1295 without DAC (Mod GRF 1-29), Modified GRF 1-29

Share:Share on Reddit

CJC-1295 is not FDA-approved for human use outside of clinical research. Information is for educational purposes only and does not constitute medical advice.

📚 Content aggregated from:2 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone and is almost universally used in combination with a GHRP like Ipamorelin to produce a more physiological GH pulse.

Research Summary

Studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 levels. The DAC (Drug Affinity Complex) version extends the half-life to approximately 6–8 days via albumin binding, while Mod GRF 1-29 has a much shorter half-life (~30 minutes) and is dosed more acutely. Research in adults with GH deficiency has shown improved body composition and metabolic markers.

Dosing Range

low

100mcg

moderate

200mcg

high

300mcg

Units: mcg · Frequency: once daily (Mod GRF) or twice weekly (DAC version)

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Subcutaneous injection (most common)Intramuscular injection

Reconstitution Notes

Reconstitute with 2 mL bacteriostatic water per 2 mg vial. Store refrigerated at 2–8°C. Use within 30 days. Protect from light and avoid shaking.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Water retention (especially early in protocol)
Tingling or numbness in extremities
Injection site redness
Flushing (transient, shortly after injection)
Fatigue or lethargy (uncommon)

Research Papers

2 peer-reviewed sources

Long-lasting growth hormone (GH)-releasing effect of a modified GRF(1-29) molecule

Journal of Clinical Endocrinology & Metabolism2006

CJC-1295 dose-dependent increases in plasma growth hormone concentration

Growth Hormone & IGF Research2006

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

Reddit r/Peptides

Comprehensive thread on CJC-1295 + Ipamorelin stacking protocols. Community consensus gravitates toward 200/200 mcg pre-sleep dosing for recovery and body composition goals.

View original thread

Reddit r/steroids (Peptides Megathread)

Long-running community resource comparing CJC-1295 DAC vs. Mod GRF 1-29. Key debate: DAC provides convenience but less physiological pulse; Mod GRF is more pulsatile but requires daily injections.

View original thread

DAC vs. Without DAC — A Key Distinction

CJC-1295 exists in two meaningful forms, and confusing them is common:

CJC-1295 DAC: Contains a Drug Affinity Complex that binds to serum albumin, dramatically extending the half-life to 6–8 days. Results in a sustained elevation of GH rather than a discrete pulse.
CJC-1295 without DAC (Mod GRF 1-29): Half-life of ~30 minutes. Used just before sleep or training to create a discrete, pulsatile GH release — more closely mimicking natural physiology.

Most performance-focused community protocols prefer Mod GRF 1-29 for this reason.

The Standard Stack: CJC-1295 + Ipamorelin

CJC-1295 is a GHRH analog — it tells the pituitary to release GH. Ipamorelin is a GHRP (growth hormone releasing peptide) — it amplifies that signal. Using both together creates a synergistic effect on GH output that is greater than either alone.

Typical community protocol:

100–200 mcg CJC-1295 (Mod GRF) + 100–200 mcg Ipamorelin
Injected subcutaneously 30 minutes before sleep
5 days on / 2 days off, or continuous for 8–16 weeks

Research Context

Human trials have primarily been in adults with GH deficiency or age-related GH decline. Results showed increases in IGF-1 of 28–43% over baseline across multiple doses and timeframes. Long-term safety data in healthy, GH-replete adults is limited.